Baymatob, a Sydney-based developer of AI-guided maternity sensors, has raised $6.5M in Series A3 funding. The round supports its Oli platform, which uses a wearable sensor and AI to predict postpartum hemorrhage risk up to nine hours before delivery. The capital will fund completion of pivotal clinical trials in Australia and the US, regulatory submissions to TGA and FDA, manufacturing scale-up, and commercial launch.
PPH Prediction Draws Healthcare Capital
The timing aligns with rising focus on preventable maternal deaths. Baymatob's approach uses multi-sensor data and AI for pre-delivery risk prediction, unlike reactive monitoring tools. This addresses gaps where current systems lose contact or provide subjective alerts during labor.
Preventable Maternal Deaths Persist
Postpartum hemorrhage affects around one in five births in Australia and leads to 70,000 deaths globally each year. More than 80% of deaths during and after pregnancy are preventable, according to CDC data. Existing monitoring has remained largely unchanged for over sixty years, often failing to give clinicians advance warning.
Oli Delivers Objective Early Warnings
Oli captures millions of data points from 10 biosensors to forecast hemorrhage risk at least one hour before birth in many cases. The system provides objective detection instead of subjective assessment, giving teams time to intervene. CEO Tara Croft noted the limitations of today's tools:
"In birth rooms today, the monitoring meant to protect the room is failing the people in it – losing contact with mother and baby, misfiring, and demanding constant attention from the team it was supposed to free."
The platform holds FDA Breakthrough Device Designation and is positioned for over 15 future maternity applications using the same core sensor technology.
Healthcare Fund Validates Clinical Focus
Future of Healthcare Fund from Australian Unity led as cornerstone investor, alongside Scale Investors, Clare Ventures, and University of Sydney. The backing from an established healthcare-focused fund signals strong institutional confidence in regulated medtech solutions for women's health.
Maternal Monitoring Market Expands
The postpartum hemorrhage devices market is projected to grow from $1.08 billion in 2026 to $1.38 billion by 2031 at a 5.05% CAGR. Broader fetal monitoring equipment sits at $6.16 billion with 6.8% CAGR. Policy support including the US Congress FY2026 funding bill for maternal health innovation creates tailwinds for predictive tools like Oli.
Clinical Momentum Builds Toward Launch
With pivotal trials now recruiting at multiple sites including Woman's Hospital in Baton Rouge, Columbia University, and Royal North Shore Hospital, Baymatob is preparing for regulatory clearance and market entry. The company has also secured $1.3M in non-dilutive NSW Health Medical Devices Fund support to accelerate development.